JPTL
2021-08-24
👍
After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":834117445,"tweetId":"834117445","gmtCreate":1629779507187,"gmtModify":1631892318507,"author":{"id":3585350696038563,"idStr":"3585350696038563","authorId":3585350696038563,"authorIdStr":"3585350696038563","name":"JPTL","avatar":"https://static.tigerbbs.com/6f6dde4c2c1d83e8d80141b547948419","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>👍</p></body></html>","htmlText":"<html><head></head><body><p>👍</p></body></html>","text":"👍","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/834117445","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","kind":"news","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=full","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8 <a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CWH":"露营世界","PANW":"Palo Alto Networks","MOS":"美国美盛","BXC":"布鲁林克斯","GEVO":"Gevo Inc.","FLXS":"Flexsteel Inds","TBPH":"Theravance Biopharma Inc.","MARK":"Remark控股","CARA":"Cara Therapeutics"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1,"symbols_score_info":{"BXC":0.9,"CARA":0.9,"CWH":0.9,"FLXS":0.9,"GEVO":0.9,"MARK":0.9,"MOS":0.9,"PANW":0.9,"TBPH":0.9}},"isVote":1,"tweetType":1,"viewCount":204,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/834117445"}
精彩评论